Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages

GLIA

Volumn 64, Issue 12, 2016, Pages 2181-2200

  Guglielmetti, Caroline ^a   Le Blon, Debbie ^a   Santermans, Eva ^b   Salas Perdomo, Angelica ^c   Daans, Jasmijn ^a   De Vocht, Nathalie ^a   Shah, Disha ^a   Hoornaert, Chloé ^a   Praet, Jelle ^a   Peerlings, Jurgen ^a   Kara, Firat ^a   Bigot, Christian ^a   Mai, Zhenhua ^a,d   Goossens, Herman ^a   Hens, Niel ^a,b   Hendrix, Sven ^b   Verhoye, Marleen ^a   Planas, Anna M ^c   Berneman, Zwi ^a   van der Linden, Annemie ^a   Ponsaerts, Peter ^a   more..

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d IcoMetrix   (Belgium)

Author keywords

demyelination; magnetic resonance imaging; multiple sclerosis

Indexed keywords

ARG 1 PROTEIN; CHITINASE; CHITINASE LIKE 3; CUPRIZONE; GALECTIN 3; INTERLEUKIN 13; LENTIVIRUS VECTOR; PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; DIFFERENTIATION ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; MONOAMINE OXIDASE INHIBITOR; MONOCYTE-MACROPHAGE DIFFERENTIATION ANTIGEN; MYELIN PROTEIN; NERVE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CELL DEATH; CENTRAL NERVOUS SYSTEM INFLAMMATION; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; INFLAMMATORY CELL; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PHENOTYPE; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CHEMICALLY INDUCED; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; ENCEPHALITIS; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; MACROPHAGE; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, DIFFERENTIATION; BONE MARROW TRANSPLANTATION; CUPRIZONE; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENCEPHALITIS; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; INTERLEUKIN-13; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MONOAMINE OXIDASE INHIBITORS; MYELIN PROTEINS; NERVE TISSUE PROTEINS; TRANSDUCTION, GENETIC;

EID: 84989333166     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.23053     Document Type: Article

References (101)

1. Acs P, Kipp M, Norkute A, Johann S, Clarner T, Braun A, Berente Z, Komoly S, Beyer C. 2009. 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57:807–814.
2. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. 2001. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116–1122.
3. Baekelandt V, Eggermont K, Michiels M, Nuttin B, Debyser Z. 2003. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther 10:1933–1940.
4. Boretius S, Escher A, Dallenga T, Wrzos C, Tammer R, Bruck W, Nessler S, Frahm J, Stadelmann C. 2012. Assessment of lesion pathology in a new animal model of MS by multiparametric MRI and DTI. Neuroimage 59:2678–2688.
5. Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, Olivecrona G, Klein RS, Cross AH, Otero K, Piccio L. 2015. TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol 129:429–447.
6. Cash E, Minty A, Ferrara P, Caput D, Fradelizi D, Rott O. 1994. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol 153:4258–4267.
7. Chan WY, Kohsaka S, Rezaie P. 2007. The origin and cell lineage of microglia: New concepts. Brain Res Rev 53:344–354.
8. Chandran P, Upadhyay J, Markosyan S, Lisowski A, Buck W, Chin CL, Fox G, Luo F, Day M. 2012. Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice. Neuroscience 202:446–453.
9. Cherry JD, Olschowka JA, O'Banion MK. 2014. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J Neuroinflammation 11:98.
10. David S, Kroner A. 2011. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 12:388–399.
11. De Vocht N, Lin D, Praet J, Hoornaert C, Reekmans K, Le Blon D, Daans J, Pauwels P, Goossens H, Hens N, Berneman Z, Van der Linden A, Ponsaerts P. 2013. Quantitative and phenotypic analysis of mesenchymal stromal cell graft survival and recognition by microglia and astrocytes in mouse brain. Immunobiology 218:696–705.
12. Dhakal M, Hardaway JC, Guloglu FB, Miller MM, Hoeman CM, Zaghouani AA, Wan X, Rowland LM, Cascio JA, Sherman MP, Zaghouani H. 2014. IL-13Ralpha1 is a surface marker for M2 macrophages influencing their differentiation and function. Eur J Immunol 44:842–855.
13. Fjaer S, Bo L, Lundervold A, Myhr KM, Pavlin T, Torkildsen O, Wergeland S. 2013. Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLoS One 8:e84162.
14. Franco R, Fernandez-Suarez D. 2015. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 131:65–86.
15. Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R. 2005. Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 7:1299–1310.
16. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330:841–845.
17. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. 2013. Origin and differentiation of microglia. Front Cell Neurosci 7:45.
18. Giunti D, Parodi B, Cordano C, Uccelli A, Kerlero de Rosbo N. 2014. Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. Immunology 141:328–339.
19. Goldmann T, Prinz M. 2013. Role of microglia in CNS autoimmunity. Clin Dev Immunol 2013:208093.
20. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3:23–35.
21. Grossman RI. 1994. Magnetization transfer in multiple sclerosis. Ann Neurol 36 Suppl:S97–99.
22. Gudi V, Gingele S, Skripuletz T, Stangel M. 2014. Glial response during cuprizone-induced de- and remyelination in the CNS: Lessons learned. Front Cell Neurosci 8:73.
23. Gudi V, Moharregh-Khiabani D, Skripuletz T, Koutsoudaki PN, Kotsiari A, Skuljec J, Trebst C, Stangel M. 2009. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res 1283:127–138.
24. Gudi V, Skuljec J, Yildiz O, Frichert K, Skripuletz T, Moharregh-Khiabani D, Voss E, Wissel K, Wolter S, Stangel M. 2011. Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS One 6:e22623.
25. Guglielmetti C, Praet J, Rangarajan JR, Vreys R, De Vocht N, Maes F, Verhoye M, Ponsaerts P, Van der Linden A. 2014. Multimodal imaging of subventricular zone neural stem/progenitor cells in the cuprizone mouse model reveals increased neurogenic potential for the olfactory bulb pathway, but no contribution to remyelination of the corpus callosum. Neuroimage 86:99–110.
26. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS. 2008. Recovery from chronic demyelination by thyroid hormone therapy: Myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci 28:14189–14201.
27. Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, Matsushima GK. 1998. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 92:38–49.
28. Hoornaert CJ, Luyckx E, Reekmans K, Dhainaut M, Guglielmetti C, Le Blon D, Dooley D, Fransen E, Daans J, Verbeeck L, Quarta A, De Vocht N, Lemmens E, Goossens H, Van der Linden A, Roobrouck VD, Verfaillie C, Hendrix S, Moser M, Berneman ZN, Ponsaerts P. 2016. In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell Implants. Stem Cells 34:1971–1984.
29. Houghton BC, Booth C, Thrasher AJ. 2015. Lentivirus technologies for modulation of the immune system. Curr Opin Pharmacol 24:119–127.
30. Hu X, Li P, Guo Y, Wang H, Leak RK, Chen S, Gao Y, Chen J. 2012. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43:3063–3070.
31. Janssens K, Maheshwari A, Van den Haute C, Baekelandt V, Stinissen P, Hendriks JJ, Slaets H, Hellings N. 2015. Oncostatin M protects against demyelination by inducing a protective microglial phenotype. Glia 63:1729–1737.
32. Kawahara K, Suenobu M, Yoshida A, Koga K, Hyodo A, Ohtsuka H, Kuniyasu A, Tamamaki N, Sugimoto Y, Nakayama H. 2012. Intracerebral microinjection of interleukin-4/interleukin-13 reduces beta-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice. Neuroscience 207:243–260.
33. Kay MA. 2011. State-of-the-art gene-based therapies: The road ahead. Nat Rev Genet 12:316–328.
34. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. 2003. Interleukin-4 and interleukin-13 signaling connections maps. Science 300:1527–1528.
35. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. 2011. Physiology of microglia. Physiol Rev 91:461–553.
36. Kipp M, Clarner T, Dang J, Copray S, Beyer C. 2009. The cuprizone animal model: New insights into an old story. Acta Neuropathol 118:723–736.
37. Lampron A, Larochelle A, Laflamme N, Prefontaine P, Plante MM, Sanchez MG, Yong VW, Stys PK, Tremblay ME, Rivest S. 2015. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med 212:481–495.
38. Lassmann H, van Horssen J. 2016. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. Biochim Biophys Acta 1862:506–510.
39. Le Blon D, Hoornaert C, Daans J, Santermans E, Hens N, Goossens H, Berneman Z, Ponsaerts P. 2014. Distinct spatial distribution of microglia and macrophages following mesenchymal stem cell implantation in mouse brain. Immunol Cell Biol 92:650–658.
40. Liu C, Li Y, Yu J, Feng L, Hou S, Liu Y, Guo M, Xie Y, Meng J, Zhang H, Xiao B, Ma C. 2013. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One 8:e54841.
41. London A, Cohen M, Schwartz M. 2013. Microglia and monocyte-derived macrophages: Functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci 7:34.
42. Ma SF, Chen YJ, Zhang JX, Shen L, Wang R, Zhou JS, Hu JG, Lu HZ. 2015. Adoptive transfer of M2 macrophages promotes locomotor recovery in adult rats after spinal cord injury. Brain Behav Immun 45:157–170.
43. Mahad DH, Trapp BD, Lassmann H. 2015. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 14:183–193.
44. Malam Y, Loizidou M, Seifalian AM. 2009. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592–599.
45. Martinez FO, Gordon S. 2014. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Rep 6:13.
46. Matrai J, Chuah MK, VandenDriessche T. 2010. Recent advances in lentiviral vector development and applications. Mol Ther 18:477–490.
47. Matsushima GK, Morell P. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107–116.
48. Merkler D, Boretius S, Stadelmann C, Ernsting T, Michaelis T, Frahm J, Bruck W. 2005. Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 18:395–403.
49. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. 2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164:6166–6173.
50. Miro-Mur F, Perez-de-Puig I, Ferrer-Ferrer M, Urra X, Justicia C, Chamorro A, Planas AM. 2016. Immature monocytes recruited to the ischemic mouse brain differentiate into macrophages with features of alternative activation. Brain Behav Immun 53:18–33.
51. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJ, ffrench-Constant C. 2013. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16:1211–8.
52. Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, Matsushima GK. 1998. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220–227.
53. Morganti JM, Jopson TD, Liu S, Gupta N, Rosi S. 2014. Cranial irradiation alters the brain's microenvironment and permits CCR2+ macrophage infiltration. PLoS One 9:e93650.
54. Morganti JM, Jopson TD, Liu S, Riparip LK, Guandique CK, Gupta N, Ferguson AR, Rosi S. 2015. CCR2 antagonism alters brain macrophage polarization and ameliorates cognitive dysfunction induced by traumatic brain injury. J Neurosci 35:748–760.
55. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958–969.
56. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. 2014. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14–20.
57. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314–1318.
58. Olah M, Amor S, Brouwer N, Vinet J, Eggen B, Biber K, Boddeke HW. 2012. Identification of a microglia phenotype supportive of remyelination. Glia 60:306–321.
59. Orihuela R, McPherson CA, Harry GJ. 2016. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol 173:649–665.
60. Orije J, Kara F, Guglielmetti C, Praet J, Van der Linden A, Ponsaerts P, Verhoye M. 2015. Longitudinal monitoring of metabolic alterations in cuprizone mouse model of multiple sclerosis using 1H-magnetic resonance spectroscopy. Neuroimage 114:128–135.
61. Ou X, Sun SW, Liang HF, Song SK, Gochberg DF. 2009. The MT pool size ratio and the DTI radial diffusivity may reflect the myelination in shiverer and control mice. NMR Biomed 22:480–487.
62. Ousman SS, Kubes P. 2012. Immune surveillance in the central nervous system. Nat Neurosci 15:1096–1101.
63. Perry VH, Nicoll JA, Holmes C. 2010. Microglia in neurodegenerative disease. Nat Rev Neurol 6:193–201.
64. Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. 2015. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest 125:2161–2170.
65. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. 2011. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302.
66. Poloni G, Minagar A, Haacke EM, Zivadinov R. 2011. Recent developments in imaging of multiple sclerosis. Neurologist 17:185–204.
67. Ponomarev ED, Maresz K, Tan Y, Dittel BN. 2007. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 27:10714–10721.
68. Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P. 2014a. Cellular and molecular neuropathology of the cuprizone mouse model: Clinical relevance for multiple sclerosis. Neurosci Biobehav Rev 47:485–505.
69. Praet J, Orije J, Kara F, Guglielmetti C, Santermans E, Daans J, Hens N, Verhoye M, Berneman Z, Ponsaerts P, Van der Linden A. 2015a. Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra. NMR Biomed 28:505–513.
70. Praet J, Reekmans K, Lin D, De Vocht N, Bergwerf I, Tambuyzer B, Daans J, Hens N, Goossens H, Pauwels P, Berneman Z, Van der Linden A, Ponsaerts P. 2012. Cell type-associated differences in migration, survival, and immunogenicity following grafting in CNS tissue. Cell Transplant 21:1867–1881.
71. Praet J, Santermans E, Daans J, Le Blon D, Hoornaert C, Goossens H, Hens N, Van der Linden A, Berneman Z, Ponsaerts P. 2015b. Early Inflammatory Responses Following Cell Grafting in the CNS Trigger Activation of the Subventricular Zone: A Proposed Model of Sequential Cellular Events. Cell Transplant 24:1481–1492.
72. Praet J, Santermans E, Reekmans K, de Vocht N, Le Blon D, Hoornaert C, Daans J, Goossens H, Berneman Z, Hens N, Van der Linden A, Ponsaerts P. 2014b. Histological characterization and quantification of cellular events following neural and fibroblast(-like) stem cell grafting in healthy and demyelinated CNS tissue. Methods Mol Biol 1213:265–283.
73. Prinz M, Priller J, Sisodia SS, Ransohoff RM. 2011. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 14:1227–1235.
74. Ransohoff RM, Perry VH. 2009. Microglial physiology: Unique stimuli, specialized responses. Annu Rev Immunol 27:119–145.
75. Rawji KS, Yong VW. 2013. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol 2013:948–976
76. Reekmans K, De Vocht N, Praet J, Le Blon D, Hoornaert C, Daans J, Van der Linden A, Berneman Z, Ponsaerts P. 2013. Quantitative evaluation of stem cell grafting in the central nervous system of mice by in vivo bioluminescence imaging and postmortem multicolor histological analysis. Methods Mol Biol 1052:125–141.
77. Remington LT, Babcock AA, Zehntner SP, Owens T. 2007. Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 170:1713–1724.
78. Ropele S, Fazekas F. 2009. Magnetization transfer MR imaging in multiple sclerosis. Neuroimaging Clin N Am 19:27–36.
79. Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, Charo IF. 2010. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 5:e13693.
80. Skripuletz T, Hackstette D, Bauer K, Gudi V, Pul R, Voss E, Berger K, Kipp M, Baumgartner W, Stangel M. 2013. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 136:147–167.
81. Sriram S. 2011. Role of glial cells in innate immunity and their role in CNS demyelination. J Neuroimmunol 239:13–20.
82. Steelman AJ, Thompson JP, Li J. 2012. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci Res 72:32–42.
83. Stuckey DW, Shah K. 2014. Stem cell-based therapies for cancer treatment: Separating hope from hype. Nat Rev Cancer 14:683–691.
84. Tambuyzer BR, Ponsaerts P, Nouwen EJ. 2009. Microglia: Gatekeepers of central nervous system immunology. J Leukoc Biol 85:352–370.
85. Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, Larkin DF, McClure MO, Stauss HJ, Ritter MA, Lombardi G, George AJ. 2005. Modulation of human dendritic-cell function following transduction with viral vectors: Implications for gene therapy. Blood 105:3824–3832.
86. Tang Y, Le W. 2016. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol 53:1181–1194.
87. Thiessen JD, Zhang Y, Zhang H, Wang L, Buist R, Del Bigio MR, Kong J, Li XM, Martin M. 2013. Quantitative MRI and ultrastructural examination of the cuprizone mouse model of demyelination. NMR Biomed 26:1562–1581.
88. Torkildsen O, Brunborg LA, Thorsen F, Mork SJ, Stangel M, Myhr KM, Bo L. 2009. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Exp Neurol 215:160–166.
89. Trip SA, Miller DH. 2005. Imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 76 Suppl 3:iii11–iii18.
90. Turati L, Moscatelli M, Mastropietro A, Dowell NG, Zucca I, Erbetta A, Cordiglieri C, Brenna G, Bianchi B, Mantegazza R, Cercignani M, Baggi F, Minati L. 2015. In vivo quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice. NMR Biomed 28:327–337.
91. Van Dyken SJ, Locksley RM. 2013. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: Roles in homeostasis and disease. Annu Rev Immunol 31:317–343.
92. van Noort JM, van den Elsen PJ, van Horssen J, Geurts JJ, van der Valk P, Amor S. 2011. Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies. CNS Neurol Disord Drug Targets 10:68–81.
93. Voss EV, Skuljec J, Gudi V, Skripuletz T, Pul R, Trebst C, Stangel M. 2012. Characterisation of microglia during de- and remyelination: can they create a repair promoting environment? Neurobiol Dis 45:519–528.
94. Wattjes MP, Steenwijk MD, Stangel M. 2015. MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update. Clin Neuroradiol 25:157–165.
95. Won SY, Kim SR, Maeng S, Jin BK. 2013. Interleukin-13/Interleukin-4-induced oxidative stress contributes to death of prothrombinkringle-2 (pKr-2)-activated microglia. J Neuroimmunol 265:36–42.
96. Yang MS, Park EJ, Sohn S, Kwon HJ, Shin WH, Pyo HK, Jin B, Choi KS, Jou I, Joe EH. 2002. Interleukin-13 and −4 induce death of activated microglia. Glia 38:273–280.
97. Yang Y, Salayandia VM, Thompson JF, Yang LY, Estrada EY, Yang Y. 2015. Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery. J Neuroinflammation 12:26.
98. Yu Z, Sun D, Feng J, Tan W, Fang X, Zhao M, Zhao X, Pu Y, Huang A, Xiang Z, Cao L, He C. 2015. MSX3 Switches Microglia Polarization and Protects from Inflammation-Induced Demyelination. J Neurosci 35:6350–6365.
99. Zaaraoui W, Deloire M, Merle M, Girard C, Raffard G, Biran M, Inglese M, Petry KG, Gonen O, Brochet B, Franconi JM, Dousset V. 2008. Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4 T. magma 21:357–362.
100. Zhao X, Wang H, Sun G, Zhang J, Edwards NJ, Aronowski J. 2015. Neuronal Interleukin-4 as a Modulator of Microglial Pathways and Ischemic Brain Damage. J Neurosci 35:11281–11291.
101. Zurawski G, de Vries JE. 1994. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19–26.